Window Trial of Fluorescently Labeled Nivolumab-IRDye800 (Nivo800) in High Grade Glioma (HGG)

NCT07210632 | Recruiting Early Phase 1 DMC FDA Drug

• 1 other identifier: VICCHN25046
• Study Type: interventional
• Target: 38
• Locations: 1 country
• Sites: 1

Brief Summary

High-grade gliomas (HGGs) are among the most aggressive and treatment-resistant brain tumors. Immunotherapy with checkpoint inhibitors like nivolumab has shown promise, but its efficacy remains variable and poorly understood in this patient population. This clinical trial investigates a novel imaging-enabled formulation of nivolumab-IRDye800 (nivo800) which incorporates a near-infrared (NIR) fluorescent dye to enable real-time visualization of drug distribution within tumor tissue.

Conditions

Brain Cancer; HGG; Glioma; High Grade Glioma; High Grade Gliomas; High Grade Glioma (III or IV); High Grade Glioma (HGG) of the Brain With BRAF Aberration

Keywords

hgg; high grade glioma

Outcome Measures

Primary Outcomes (1)

• Determine the safety of fluorescently labeled nivolumab-IRDye800 (nivo800) as a molecular imaging agent via assessing adverse events.

  As defined by the number of Grade ≥ 2 Adverse Events (AEs) determined that are clinically significant and considered definitely or probably related to nivo800. Safety data will be summarized by grade, severity, and type.

  From infusion to 15 days post-infusion.

Secondary Outcomes (1)

• Determine the optimal dose of nivolumab-IRDye800 (nivo800) for near-infrared (NIR) fluorescence imaging in the tumor, via microscopic imaging.

  From Day of Surgery Resection to 3 months

Study Arms (5)

Nivo800 (5mg)

EXPERIMENTAL

5mg nivo800

Drug: Nivolumab-IRDye800

Nivo800 + Nivo (50mg +190)

EXPERIMENTAL

50 mg nivo800 +190 mg nivolumab

Drug: Nivolumab; Drug: Nivolumab-IRDye800

Nivo800 + Nivo (100mg + 140mg)

EXPERIMENTAL

100 mg nivo800 +140 mg nivolumab

Drug: Nivolumab; Drug: Nivolumab-IRDye800

Nivo800 + Nivo (150mg + 90mg)

EXPERIMENTAL

150 mg nivo800 +90 mg nivolumab

Drug: Nivolumab; Drug: Nivolumab-IRDye800

Nivo800 + Nivo (expansion at optimal dose cohort)

EXPERIMENTAL

Expansion at optimal dose

Drug: Nivolumab; Drug: Nivolumab-IRDye800

Interventions

Nivolumab-IRDye800 DRUG

Participants will receive an infusion of nivolumab-IRDye800 (nivo800). Nivo800 has never been assessed in patients before and therefore Cohort 1 will receive only a test dose to determine the safety (3 participants). Cohorts 2-4 will receive escalating doses of nivo800, keeping the overall dose nivolumab + nivo800 no more than 240 mg. Participants will undergo planned Standard of Care surgical resection at 1-4 days after infusion.

Nivo800 (5mg); Nivo800 + Nivo (100mg + 140mg); Nivo800 + Nivo (150mg + 90mg); Nivo800 + Nivo (50mg +190); Nivo800 + Nivo (expansion at optimal dose cohort)

Nivolumab DRUG

Participants will receive a single infusion of nivolumab following an infusion of nivolumab-IRDye800 (nivo800), for a combined total dose of 240 mg. This dosing applies to all cohorts except Cohort 1, which is designated as the safety group. Each cohort, other than Cohort 1, will receive no more than 240 mg in total of nivolumab and nivo800 combined. Participants will then undergo planned Standard of Care (SOC) surgical resection 1 to 4 days after the infusion.

Nivo800 + Nivo (100mg + 140mg); Nivo800 + Nivo (150mg + 90mg); Nivo800 + Nivo (50mg +190); Nivo800 + Nivo (expansion at optimal dose cohort)

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Written informed consent
• Age ≥ 18 years
• Patient must have imaging of highly suspicious high grade glioma (HGG)
• Patients for whom surgical craniotomy is planned as standard of care (SOC)
• Adequate hematologic and end-organ function appropriate for surgical resection and anesthesia (within 30 days of infusion) WBC ≥ 2,000 (mcl) AST 9-80 (IU/L) ALT 7-110 (IU/L) BUN 6-50 (mg/dL) Creatinine 0.5-3.0 (mg/dL) Negative hepatitis B surface antigen (HBsAg) test at screening

You may not qualify if:

• Patients not eligible for SOC surgical resection
• Active or history of autoimmune disease or immune deficiency, including, but not limited to, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid antibody syndrome, Wegener granulomatosis, Sjögren syndrome, Guillain-Barré syndrome, or multiple sclerosis with the following exceptions:
• Patients with a history of autoimmune-related hypothyroidism who are on thyroid-replacement hormone are eligible for the study.
• Patients with controlled Type 1 diabetes mellitus who are on an insulin regimen are eligible for the study.
• Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis are excluded) are eligible for the study provided if all the following conditions are met:
• Rash must cover \< 10% of body surface area Disease is well controlled at baseline and requires only low-potency topical corticosteroids No occurrence of acute exacerbations of the underlying condition requiring psoralen plus ultraviolet A radiation, methotrexate, retinoids, biologic agents, oral calcineurin inhibitors, or high-potency oral corticosteroids within the previous 12 months
• History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan.
• History of radiation pneumonitis in the radiation field (fibrosis) is permitted.
• Significant cardiovascular disease (such as New York Heart Association Class II or greater cardiac disease, myocardial infarction, or cerebrovascular accident) within 3 months prior to initiation of study treatment, unstable arrhythmia, or unstable angina.
• Severe unresolved infection within 4 weeks prior to initiation of study treatment.
• Prior allogeneic stem cell or solid organ transplantation
• History of severe allergic anaphylactic reactions to chimeric or humanized antibodies or fusion proteins
• Chronic treatment with systemic immunosuppressive medication in excess of physiologic maintenance doses of corticosteroids (\>10 mg/day of prednisone or equivalent) (including, but not limited to, corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-TNF-a agents), with the following exceptions:
• Patients who received acute, systemic immunosuppressant medication or a dose of systemic immunosuppressant medication are eligible for the study.
• Physiologic corticosteroid replacement therapy at doses ≤ 10 mg/day of prednisone or equivalent for adrenal or pituitary insufficiency and in the absence of active autoimmune disease is permitted.

Sponsors & Collaborators

• Eben Rosenthal: lead
• Vanderbilt-Ingram Cancer Center: collaborator

Study Sites (1)

Vanderbilt University Medical Center

Nashville, Tennessee, 37232, United States

RECRUITING

MeSH Terms

Conditions

Brain Neoplasms; Glioma

Interventions

Nivolumab

Condition Hierarchy (Ancestors)

Central Nervous System Neoplasms; Nervous System Neoplasms; Neoplasms by Site; Neoplasms; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Neoplasms, Neuroepithelial; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms by Histologic Type; Neoplasms, Glandular and Epithelial; Neoplasms, Nerve Tissue

Intervention Hierarchy (Ancestors)

Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal; Antibodies; Immunoglobulins; Immunoproteins; Blood Proteins; Proteins; Amino Acids, Peptides, and Proteins; Serum Globulins; Globulins

Study Officials

• Patrick Kelly, MD

  Vanderbilt University Medical Center

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Nicole Jones

CONTACT

615-936-2807; nicole.l.jones@vumc.org

Makenna Brown

CONTACT

(615)421-4370; makenna.l.brown@vumc.org

Study Design

• Study Type: interventional
• Phase: early phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: SUPPORTIVE CARE
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Barry and Amy Baker Professor and Chair

Study Record Dates

• First Submitted: September 29, 2025
• First Posted: October 7, 2025
• Study Start: March 30, 2026
• Primary Completion (Estimated): March 30, 2030
• Study Completion (Estimated): March 30, 2031
• Last Updated: April 29, 2026

Record last verified: 2025-10

Locations

US (1)